After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Washington Post
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value and an activist investor is agitating for change.
https://www.washingtonpost.com/business/2024/10/14/pfizer-bourla-covid-vaccine-investors/